Diffusion Pharma changes design of early-stage study of TSC in COVID-19

The FDA has suggested certain study design changes related to endpoints and statistical considerations, for Diffusion Pharmaceuticals’s (DFFN -12.5%) trans sodium crocetinate (TSC) in COVID-19 patients.

The Company now expects to enroll the first patient by the end of August, vs. end of July as expected earlier, with first data available in the early next quarter.

IND for the trial was filed earlier this month.

https://seekingalpha.com/news/3595249-diffusion-pharma-changes-design-of-early-stage-study-of-tsc-in-covidminus-19